A detailed history of Royal Bank Of Canada transactions in Immunovant, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 9,683 shares of IMVT stock, worth $266,379. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,683
Previous 20,342 52.4%
Holding current value
$266,379
Previous $537,000 50.47%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$27.51 - $27.51 $293,229 - $293,229
-10,659 Reduced 52.4%
9,683 $266,000
Q2 2024

Aug 14, 2024

BUY
$25.1 - $31.61 $46,309 - $58,320
1,845 Added 9.97%
20,342 $537,000
Q1 2024

Nov 05, 2024

SELL
$30.27 - $43.79 $55,848 - $80,792
-1,845 Reduced 9.07%
18,497 $597,000
Q1 2024

May 15, 2024

SELL
$30.27 - $43.79 $642,904 - $930,055
-21,239 Reduced 53.45%
18,497 $597,000
Q4 2023

Feb 14, 2024

SELL
$31.31 - $44.19 $9,549 - $13,477
-305 Reduced 0.76%
39,736 $1.67 Million
Q3 2023

Nov 14, 2023

BUY
$18.55 - $39.96 $662,086 - $1.43 Million
35,692 Added 820.69%
40,041 $1.54 Million
Q2 2023

Aug 14, 2023

BUY
$14.2 - $23.75 $6,674 - $11,162
470 Added 12.12%
4,349 $82,000
Q1 2023

May 15, 2023

SELL
$15.27 - $19.72 $35,075 - $45,296
-2,297 Reduced 37.19%
3,879 $60,000
Q4 2022

Feb 14, 2023

BUY
$6.59 - $17.75 $30,544 - $82,271
4,635 Added 300.78%
6,176 $109,000
Q3 2022

Nov 14, 2022

BUY
$3.93 - $6.37 $1,080 - $1,751
275 Added 21.72%
1,541 $9,000
Q2 2022

Aug 15, 2022

SELL
$3.38 - $5.65 $7,662 - $12,808
-2,267 Reduced 64.17%
1,266 $5,000
Q1 2022

May 16, 2022

SELL
$5.06 - $8.77 $25,770 - $44,665
-5,093 Reduced 59.04%
3,533 $20,000
Q4 2021

Feb 14, 2022

BUY
$7.33 - $9.32 $30,991 - $39,404
4,228 Added 96.13%
8,626 $74,000
Q3 2021

Nov 15, 2021

BUY
$7.01 - $11.37 $9,035 - $14,655
1,289 Added 41.46%
4,398 $38,000
Q2 2021

Aug 16, 2021

BUY
$9.4 - $16.85 $29,224 - $52,386
3,109 New
3,109 $33,000

Others Institutions Holding IMVT

About Immunovant, Inc.


  • Ticker IMVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 129,077,000
  • Market Cap $3.55B
  • Description
  • Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...
More about IMVT
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.